{"Symbol": "NDRM", "AssetType": "Common Stock", "Name": "NeuroDerm Ltd", "Description": "NeuroDerm Ltd., a clinical-stage pharmaceutical company, engages in developing drug-device combinations for the treatment of central nervous system (CNS) disorders. The company?s levodopa and carbidopa (LD/CD) product candidates, which have completed Phase IIa clinical trial, include ND0612L and ND0612H for the treatment of patients with moderate and advanced Parkinson?s disease. It is also developing ND0701, a subcutaneously delivered apomorphine formulation for patients who suffer from moderate to severe Parkinson?s disease and who do not respond well to LD/CD; and ND0801, which is in Phase IIa clinical trial for the treatment of cognition disorders associated with CNS diseases, such as ADD/ADHD, Alzheimer?s disease, and schizophrenia. NeuroDerm Ltd. was founded in 2003 and is headquartered in Rehovot, Israel.", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "Other", "Industry": "Other", "Address": "Ruhrberg Science Building, 3 Pekeris Street\n7670212,Rehovot,ISR\n", "FullTimeEmployees": "55", "FiscalYearEnd": "December", "LatestQuarter": "None", "MarketCapitalization": "None", "EBITDA": "None", "PERatio": "None", "PEGRatio": "-0.83", "BookValue": "None", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-1.98", "RevenuePerShareTTM": "0", "ProfitMargin": "0", "OperatingMarginTTM": "0", "ReturnOnAssetsTTM": "0", "ReturnOnEquityTTM": "0", "RevenueTTM": "0", "GrossProfitTTM": "0", "DilutedEPSTTM": "0", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0", "AnalystTargetPrice": "47.5", "TrailingPE": "0", "ForwardPE": "0", "PriceToSalesRatioTTM": "0", "PriceToBookRatio": "0", "EVToRevenue": "0", "EVToEBITDA": "0", "Beta": "None", "52WeekHigh": "None", "52WeekLow": "None", "50DayMovingAverage": "0", "200DayMovingAverage": "0", "SharesOutstanding": "0", "SharesFloat": "0", "SharesShort": "0", "SharesShortPriorMonth": "0", "ShortRatio": "0", "ShortPercentOutstanding": "0", "ShortPercentFloat": "0", "PercentInsiders": "0", "PercentInstitutions": "0", "ForwardAnnualDividendRate": "0", "ForwardAnnualDividendYield": "0", "PayoutRatio": "0", "DividendDate": "None", "ExDividendDate": "None", "LastSplitFactor": "None", "LastSplitDate": "None"}